Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ADH1C | P00326 | 3/20 | 0.48 |
| ▸ | ADH1A | P07327 | 3/20 | 0.48 |
| ▸ | ADH4 | P08319 | 3/20 | 0.48 |
| ▸ | ADH1B | P00325 | 2/20 | 0.48 |
| ▸ | ADH7 | P40394 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexadecane SCHEMBL28158362 | 1.00 | TSHR (0.56) | TSHRTHRBADH1CADH1AADH4 | |
| Octane SCHEMBL8523622 | 1.00 | TSHR (0.56) | TSHRTHRBADH1CADH1AADH4 | |
| Dodecane SCHEMBL28219621 | 1.00 | TSHR (0.56) | TSHRTHRBADH1CADH1AADH4 | |
| Decane SCHEMBL27095057 | 1.00 | TSHR (0.56) | TSHRTHRBADH1CADH1AADH4 | |
| Hexane SCHEMBL913216 | 0.97 | TSHR (0.60) | TSHRTHRBADH1CADH1AADH4 | |
| Pentane SCHEMBL28217044 | 0.90 | TSHR (0.60) | TSHRTHRBADH1CADH1AADH4 | |
| Pentane SCHEMBL28141221 | 0.88 | TSHR (0.56) | TSHRTHRBADH1CADH1AADH4 | |
| Octanol SCHEMBL27660517 | 0.87 | TSHR (0.62) | TSHRTHRBADH1CADH1AADH4 | |
| Dimethylformamide SCHEMBL28799762 | 0.87 | TSHR (0.43) | TSHRTHRBADH1CADH1AADH4 | |
| Dimethylformamide SCHEMBL28261689 | 0.87 | TSHR (0.43) | TSHRTHRBADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106967094-B | The manufacturing method of hydrazine compound, the manufacturing method of optically anisotropic body and polymerizable compound | 日本瑞翁株式会社 | 2019-11-15 | — | — | CN | disclosed |
| CN-110462465-A | Liquid-crystal composition, liquid crystal cured film and its manufacturing method | ZEON CORP | 2019-11-15 | — | — | CN | disclosed |
| CN-110392850-A | Liquid crystal cured film and its manufacturing method | 日本瑞翁株式会社 | 2019-10-29 | — | — | CN | disclosed |
| CN-106278943-B | Optical thin film, polymerizable compound, polymerizable composition, polymerizable composition, macromolecule, optically anisotropic body and hydrazine compound | 日本瑞翁株式会社 | 2019-07-30 | — | — | CN | disclosed |
| CN-109072082-A | The manufacturing method of liquid crystalline composition, liquid crystal cured layer and the liquid crystal cured layer | 日本瑞翁株式会社 | 2018-12-21 | — | — | CN | disclosed |
| CN-108774293-A | Compound, the manufacturing method of polymerizable compound and hydrazine compound | 日本瑞翁株式会社 | 2018-11-09 | — | — | CN | disclosed |
| CN-108431175-A | Liquid crystalline composition, liquid crystal cured layer and its manufacturing method and optical film | 日本瑞翁株式会社 | 2018-08-21 | — | — | CN | disclosed |
| CN-105745233-B | Polymerizable compound, polymerizable composition, polymer, and optically anisotropic body | 日本瑞翁株式会社 | 2018-06-12 | — | — | CN | disclosed |
| CN-107963997-A | The manufacture method of compound, mixture and polymerizable compound | 日本瑞翁株式会社 | 2018-04-27 | — | — | CN | disclosed |
| CN-105452311-B | Polymerizable compound, polymerizable composition, polymer, and optically anisotropic body | 日本瑞翁株式会社 | 2018-01-16 | — | — | CN | disclosed |
| CN-1876824-A | Method for preparing cytosine arabinoside ester by enzyme catalysis | UNIV SOUTH CHINA TECH (CN) | 2006-12-13 | — | — | CN | disclosed |
| US-20060252794-A1 | Process for preparing 5-'(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an andrenoceptor agonist | NOVARTIS AG (CH) | 2006-11-09 | — | — | US | disclosed |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | NOVARTIS AG (CH) | 2006-08-24 | — | — | US | disclosed |
| EP-1613599-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| EP-1599450-A1 | PROCESS FOR PREPARING 5-\"(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMIN O)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| EP-1487782-A1 | PROCESS FOR PREPARING NATEGLINIDE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004087668-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004076422-A1 | PROCESS FOR PREPARING 5-‘(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMINO)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004005240-A1 | PROCESS FOR PREPARING NATEGLINIDE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-01-15 | — | — | WO | disclosed |
| US-4197242-A | USED AS PIGMENTS, PHOTORECEPTORS | XEROX CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252794-A1 | Process for preparing 5-'(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an andrenoceptor agonist | OPRL1, HTR5A, HTR7 | TSHR 233/4885THRB 875/4885ADH1C 434/4885 |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | UGT8, KAT8, UGT1A8 | TSHR 1260/4885THRB 2260/4885ADH1C 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.